These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 31392570)
1. Asparaginase-induced hepatotoxicity: rapid development of cholestasis and hepatic steatosis. Kamal N; Koh C; Samala N; Fontana RJ; Stolz A; Durazo F; Hayashi PH; Phillips E; Wang T; Hoofnagle JH; Hepatol Int; 2019 Sep; 13(5):641-648. PubMed ID: 31392570 [TBL] [Abstract][Full Text] [Related]
2. Levocarnitine and vitamin B complex for the treatment of pegaspargase-induced hepatotoxicity: A case report and review of the literature. Blackman A; Boutin A; Shimanovsky A; Baker WJ; Forcello N J Oncol Pharm Pract; 2018 Jul; 24(5):393-397. PubMed ID: 28523950 [TBL] [Abstract][Full Text] [Related]
3. Pegaspargase: a review of clinical studies. Graham ML Adv Drug Deliv Rev; 2003 Sep; 55(10):1293-302. PubMed ID: 14499708 [TBL] [Abstract][Full Text] [Related]
4. Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia. Schulte R; Hinson A; Huynh V; Breese EH; Pierro J; Rotz S; Mixon BA; McNeer JL; Burke MJ; Orgel E Cancer Med; 2021 Nov; 10(21):7551-7560. PubMed ID: 34528411 [TBL] [Abstract][Full Text] [Related]
5. Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma. August KJ; Farooki S; Fulbright JM; August A; Portnoy JM; Pommert L; Burke MJ; Guest EM Pediatr Blood Cancer; 2020 Jan; 67(1):e28021. PubMed ID: 31571395 [TBL] [Abstract][Full Text] [Related]
6. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659 [TBL] [Abstract][Full Text] [Related]
7. Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial. Patel B; Kirkwood AA; Dey A; Marks DI; McMillan AK; Menne TF; Micklewright L; Patrick P; Purnell S; Rowntree CJ; Smith P; Fielding AK Leukemia; 2017 Jan; 31(1):58-64. PubMed ID: 27480385 [TBL] [Abstract][Full Text] [Related]
8. PEGging down risk factors for peg-asparaginase hepatotoxicity in patients with acute lymphoblastic leukemia Rausch CR; Marini BL; Benitez LL; Elias A; Burke PW; Bixby D; Perissinotti AJ Leuk Lymphoma; 2018 Mar; 59(3):617-624. PubMed ID: 28718698 [TBL] [Abstract][Full Text] [Related]
9. The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance. Horvat TZ; Pecoraro JJ; Daley RJ; Buie LW; King AC; Rampal RK; Tallman MS; Park JH; Douer D Leuk Res; 2016 Nov; 50():17-20. PubMed ID: 27631159 [TBL] [Abstract][Full Text] [Related]
10. Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4 Schore RJ; Devidas M; Bleyer A; Reaman GH; Winick N; Loh ML; Raetz EA; Carroll WL; Hunger SP; Angiolillo AL Leuk Lymphoma; 2019 Jul; 60(7):1740-1748. PubMed ID: 30626253 [TBL] [Abstract][Full Text] [Related]
15. A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children's Cancer Group study (CCG-1962). Kurre HA; Ettinger AG; Veenstra DL; Gaynon PS; Franklin J; Sencer SF; Reaman GH; Lange BJ; Holcenberg JS J Pediatr Hematol Oncol; 2002; 24(3):175-81. PubMed ID: 11990302 [TBL] [Abstract][Full Text] [Related]
16. Pegaspargase-induced hypertriglyceridemia in a patient with acute lymphoblastic leukemia. Lau KM; Saunders IM; Goodman A J Oncol Pharm Pract; 2020 Jan; 26(1):193-199. PubMed ID: 30823860 [TBL] [Abstract][Full Text] [Related]
17. [Therapeutic alternatives to native L-asparaginase in the treatment of adult acute lymphoblastic leukemia]. Thomas X; Cannas G; Chelghoum Y; Gougounon A Bull Cancer; 2010 Sep; 97(9):1105-17. PubMed ID: 20693115 [TBL] [Abstract][Full Text] [Related]